CN102452986A - N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof - Google Patents
N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof Download PDFInfo
- Publication number
- CN102452986A CN102452986A CN2010105120177A CN201010512017A CN102452986A CN 102452986 A CN102452986 A CN 102452986A CN 2010105120177 A CN2010105120177 A CN 2010105120177A CN 201010512017 A CN201010512017 A CN 201010512017A CN 102452986 A CN102452986 A CN 102452986A
- Authority
- CN
- China
- Prior art keywords
- methyl
- amino
- formyl radical
- hydroxy
- hexanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 66
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 53
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- -1 sec.-propyl Chemical group 0.000 claims description 29
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 24
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000002662 enteric coated tablet Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000003978 infusion fluid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000523 sample Substances 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 108010026809 Peptide deformylase Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- UCOSRTUSVXHIMK-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanamine Chemical compound C1=CC=C2NC(CN)=NC2=C1 UCOSRTUSVXHIMK-UHFFFAOYSA-N 0.000 description 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 0 *[C@@](C1=Nc2cc(*)c(*)cc2*1)N Chemical compound *[C@@](C1=Nc2cc(*)c(*)cc2*1)N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000009631 Broth culture Methods 0.000 description 4
- 150000001555 benzenes Chemical class 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000002512 suppressor factor Substances 0.000 description 4
- FEUFEGJTJIHPOF-UHFFFAOYSA-N 2-butyl acrylic acid Chemical compound CCCCC(=C)C(O)=O FEUFEGJTJIHPOF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KNHILTGJGIBGTM-UHFFFAOYSA-N C(C1=CC=CC=C1)CC(C)=NO.[O] Chemical compound C(C1=CC=CC=C1)CC(C)=NO.[O] KNHILTGJGIBGTM-UHFFFAOYSA-N 0.000 description 3
- JCWOENYFKQCGJZ-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NO.[O] Chemical compound Cl.C(C1=CC=CC=C1)NO.[O] JCWOENYFKQCGJZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- MCRZWYDXIGCFKO-UHFFFAOYSA-N 2-butylpropanedioic acid Chemical compound CCCCC(C(O)=O)C(O)=O MCRZWYDXIGCFKO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- RPNFNBGRHCUORR-UHFFFAOYSA-N diethyl 2-butylpropanedioate Chemical compound CCCCC(C(=O)OCC)C(=O)OCC RPNFNBGRHCUORR-UHFFFAOYSA-N 0.000 description 2
- ILUCPNVXZDZFIT-UHFFFAOYSA-N ethyl 2-methylidenehexanoate Chemical compound CCCCC(=C)C(=O)OCC ILUCPNVXZDZFIT-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- LJTYNLPHQVDDKN-UHFFFAOYSA-N CCCCC(CN(C=O)OCc1ccccc1)C(O)=O Chemical compound CCCCC(CN(C=O)OCc1ccccc1)C(O)=O LJTYNLPHQVDDKN-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to N-formyl hydroxylamine compounds, a preparation method thereof, and purposes thereof. The invention provides compounds represented by a formula I, enantiomers thereof, or racemic mixtures thereof. In the formula, X is O, NH, or S; R1 is H, C1-C5 straight chain or branched chain alkyl; R2 and R3 are independent H, C1-C5 straight chain or branched chain alkyl, -OR', -SR', - halogen, -CN, -CONR', -COOR' or COR', wherein R' is H, C1-C5 straight chain or branched chain alkyl. The invention also provides a method for preparing the compounds, medicine compositions containing the compounds, and purposes of the compounds. The compounds provided by the invention can be used for preventing and/or treating infectious diseases, and can be used for preparing antibacterial medicines.
Description
Technical field
The invention belongs to medical technical field, particularly, the present invention relates to N-formyl hydroxylamine compound as peptide deformylase (PDF) suppressor factor.
Background technology
The incidence of infection is higher in China; In recent years; Because antibiotic being widely used, resistant organism rolls up and spreads, and makes that new antibiotic market life is shorter and shorter; Press for and strengthen antibiotic rational use of drug, also should accelerate the antibiotic exploitation of novel texture simultaneously to reduce the generation of resistant organism.
Peptide deformylase (Peptide deformylase; PDF) be a kind of metallopeptidase that is present in prokaryotic organism such as the bacterium; By its catalytic peptide piptonychia acidylate is the essential process in intestinal bacteria and the most bacterial metabolism, and this process does not exist in the plastosome of Mammals and fungi.Therefore, be that target spot designs or synthetic PDF enzyme inhibitors class new antibiotic becomes a tempting target with this process.In screening to the PDF suppressor factor, it is found that BB-3497 is a kind of strong PDF suppressor factor of synthetic, a series of subsequently verivates are synthesized out.
Bibliographical information have PDF to suppress active compound to have following several types: N-formyl azanol class BB-3497 (Clements, J.M.et al. (2001) Antimicrob.Agents Chemother.45 (2), 563-570; Cynamon, M.H.et al. (2004) J.Antimicrob.Chemother.53 (2), 403-405); Non-peptide class (Jayasekera, M.M.K.et al. (2000) Arch.Biochem.Biophys.381,313-316); Hydroxamic acid (Apfel, C.et al. (2000) J.Med.Chem.43,2324-2331; Apfel, C.et al, (2001) J.Med.Chem.44,1847-1852); The peptide aldehydes (Durand, D.J.et al. (1999) Arch.Biochem.Biophys.367 (2), 297-302), and other (Huntington, K.M.et al. (2000) Biochemistry.39 (15), 4543-4551).But also there is not the medicine listing at present.Because PDF extensively distributes in bacterium, the PDF suppressor factor might become extensive pedigree antibiotic, therefore, is the research direction of good new antibacterials.
Disclose in the one Chinese patent application 200810053273.7 and a kind ofly contain 1, hydroxamic acid derivatives, the Preparation Method And The Use of 3-two assorted five-membered ring fused benzenes wherein disclosedly contain 1, and the structural formula of the hydroxamic acid derivatives of 3-two assorted five-membered ring fused benzenes is following:
But the polarity of hydroxamic group is big in this structural formula, change easily.
Summary of the invention
For the polarity of improving the hydroxamic group in the hydroxamic acid structure is big, the shortcoming of change the invention provides a kind of N-formyl hydroxylamine compound easily, and the preparation method of this compound comprises the purposes of pharmaceutical composition and this compound of this compound.
One object of the present invention is that the antibacterials from new mechanism searching new texture provide the compound shown in a kind of formula I or its enantiomorph or racemic mixture.
Another object of the present invention is, the preparation method of above-claimed cpd is provided.
Another purpose of the present invention is, a kind of pharmaceutical composition that comprises above-claimed cpd or its enantiomorph or racemic mixture is provided.
A further object of the present invention is, provides above-claimed cpd or its enantiomorph or racemic mixture to prevent and/or treat the purposes in the medicine of infection in preparation.
The present invention realizes that the technical scheme of above-mentioned purpose is following:
On the one hand, the present invention provides the compound shown in a kind of formula I or its enantiomorph or racemic mixture,
Wherein, X is O, NH or S; R
1Be H, C
1-C
5The straight or branched alkyl; R
2And R
3Be H, C independently
1-C
5Straight chained alkyl ,-OR ' ,-SR ' ,-halogen ,-CN ,-CONR ' ,-COOR ' or-COR ', wherein, R ' is H, C
1-C
5The straight or branched alkyl.
Preferably, in formula I, X is O, NH or S; R
1Be H, sec.-propyl, methyl, ethyl, n-propyl, normal-butyl, isobutyl-or the tertiary butyl; R
2And R
3Be independently H, methyl, ethyl, n-propyl, sec.-propyl, hydroxyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy, first sulfydryl, second sulfydryl, fluorine, chlorine, bromine ,-CN ,-COOR ', CONR ' or-COR '; Wherein, R ' is methyl, ethyl, n-propyl or sec.-propyl.
Preferably, said compound is:
N-(methyl-the 2-of benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-tolimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-oxyethyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(methyl-the 2-of 5-itrile group benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxycarbonyl benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-chloro benzimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5,6-benzoxazole dimethyl-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-methylbenzothiazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-first aminocarbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide; Or
N-(6-first carbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide.
On the other hand, the present invention provides a kind of preparation method of above-claimed cpd, and this preparation method comprises the steps:
(1) compound shown in the formula III and 2-[(N-benzyloxy-N-formyl radical amino) methyl] caproic acid is at catalyzer, and for example 4,6-dimethoxy-2-chloro-1; 3; Under the effect of 5-triazine (CDMT) and/or N-methylmorpholine (NMM), with organic solvent, for example methylene dichloride is a solvent; Under room temperature, react the compound shown in the production II at 0 ℃; And
(2) compound shown in the formula II that step (1) is generated is with reductive agent, for example with H
2Reduce with 10%Pd/C, with organic solvent, for example ethanol is solvent, reacts deprotection under the room temperature, obtains the compound shown in the formula I;
Wherein, R
1, R
2And R
3Implication with aforementioned definitions.
Another aspect, the present invention provides a kind of pharmaceutical composition, and this pharmaceutical composition comprises above-claimed cpd or its enantiomorph or racemic mixture.
Preferably, said pharmaceutical composition also comprises one or more pharmaceutically acceptable carriers, vehicle and/or thinner.
Preferably, said pharmaceutical composition is solid orally ingestible, liquid oral medicine or injection.
Preferably, said pharmaceutical composition is tablet, dispersible tablet, enteric coated tablet, chewable tablet, oral cavity disintegration tablet, capsule, sugar-coat agent, granule, dry powder doses, oral solution, the little pin of injection, injection freeze-dried powder or infusion solutions.
Again on the one hand, the present invention provides above-claimed cpd or its enantiomorph or racemic mixture to prevent and/or treat the medicine of infection, the for example purposes in the antibacterials in preparation.
Below will describe the present invention.
Compound of the present invention has the structure shown in the formula I:
Wherein, X can be O, NH or S; R
1Be H, C
1-C
5The straight or branched alkyl; R
2And R
3Can be H, C independently
1-C
5Straight chained alkyl ,-OR ' ,-SR ' ,-halogen ,-CN ,-CONR ' ,-COOR ' or-COR ', wherein, R ' can be for containing H, C
1-C
5The straight or branched alkyl.R
2And R
3Can adopt identical or different substituting group.
Preferably, among the formula I, X can O, NH or S; R
1Can be H, sec.-propyl, methyl, ethyl, n-propyl, normal-butyl, isobutyl-or the tertiary butyl; R
2And R
3Can for H, methyl, ethyl, n-propyl, sec.-propyl, hydroxyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy, first sulfydryl, second sulfydryl, fluorine, chlorine, bromine ,-CN ,-COOR ', CONR ' or-COR '; Wherein, R ' can be methyl, ethyl, n-propyl or sec.-propyl.R
2And R
3Can adopt identical or different substituting group.
Examples for compounds of the present invention is following:
N-(methyl-the 2-of benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-tolimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-oxyethyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(methyl-the 2-of 5-itrile group benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxycarbonyl benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-chloro benzimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5,6-benzoxazole dimethyl-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-methylbenzothiazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-first aminocarbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide; And
N-(6-first carbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide.
Compound shown in the formula I of the present invention can exist with optically active isomer, racemic modification or diastereomeric form, the present invention includes all enantiomorphs and composition thereof.
The preparation method of The compounds of this invention comprises the steps:
(1) compound shown in the formula III and 2-[(N-benzyloxy-N-formyl radical amino) methyl] caproic acid is at catalyzer, and for example 4,6-dimethoxy-2-chloro-1; 3; Under the effect of 5-triazine (CDMT) and/or N-methylmorpholine (NMM), with organic solvent, for example methylene dichloride is a solvent; Under room temperature, react the compound shown in the production II at 0 ℃; And
(2) compound shown in the formula II that step (1) is generated is with reductive agent, for example with H
2Reduce with 10%Pd/C, with organic solvent, for example ethanol is solvent, reacts deprotection under the room temperature, obtains the compound shown in the formula I;
Wherein, R
1, R
2And R
3Implication with aforementioned definitions.
Wherein, Compound shown in the formula III can adopt any methods known in the art to obtain; For example the compound shown in the formula III is 1, the aminated compounds of 3-two assorted five-membered ring fused benzenes, and it can adopt, and disclosed method prepares in the one Chinese patent application 200810053273.7; Particularly, can adopt following prepared in reaction:
In the above reaction formula, R is suitable amido protecting group, R
1, R
2And R
3Implication with aforementioned definitions, THF: THF, HOBt:1-hydroxyl-benzo-triazole; DCC:N, N '-dicyclohexyl carbimide.
Wherein, 2-[(N-benzyloxy-N-formyl radical is amino) methyl] caproic acid also can adopt any methods known in the art to obtain, and for example 2-[(N-benzyloxy-N-formyl radical is amino) methyl] caproic acid can adopt and be prepared as follows the route acquisition:
In the above-mentioned reaction, reaction conditions is: (a) BuBr, NaOEt, r.f.; (b) NaOH, EtOH/H
2O, r.t.; (c) HCHO, pyridine, ACN; (d) EtOH, 98%H
2SO
4, r.f.; (e) KOH, MeOH, r.t.; (f) DBU, ACN, N
2, r.f.; (g) LiOHH
2O, MeOH/H
2O, r.t.
To obtain containing different substituted 1, the aminated compounds of 3-two assorted five-membered ring fused benzenes carries out coupling (for example under the catalysis of CDMT, NMM, carrying out) with 2-[(N-benzyloxy-N-formyl radical amino) methyl] caproic acid, then with for example H
2With just obtained a series of target compound behind the 10%Pd/C reduction deprotection.
Compound of the present invention or its enantiomorph or racemic mixture; Can be prepared into pharmaceutical composition with one or more pharmaceutically acceptable carriers, vehicle and/or thinner, these pharmaceutical compositions can comprise solid orally ingestible, liquid oral medicine, injection etc.These pharmaceutical compositions can be tablet, dispersible tablet, enteric coated tablet, chewable tablet, oral cavity disintegration tablet, capsule, sugar-coat agent, granule, dry powder doses, oral solution, the little pin of injection, injection freeze-dried powder or infusion solutions.
When oral administration, pharmaceutical composition can be mixed with tablet, dispersible tablet, sugar-coat agent, granule, dry powder doses, solution or capsule, and the preparation combination of oral medication can adopt lactose or starch to do carrier; Adopt gelatin, Xylo-Mucine, methylcellulose gum, Vinylpyrrolidone polymer etc. to do a suitable wedding agent or an one-tenth agent; Disintegrating agent can be selected starch or Microcrystalline Cellulose for use; Suitable antiadhesives and lubricant can be talcum powder, santocedl, stearin, calcium stearate or magnesium etc.
Can adopt any known systems to come pharmaceutical compositions.For example; Can prepare tablet through the compacting wet granular; Activeconstituents and carrier can be optionally and the disintegrating agent composition mixture; The aqs soln of this mixture and tackiness agent, alcoholic solution or moisture-alcoholic solution carry out prilling in suitable device, dried particles adds other disintegrating agent, lubricant and antisticking agent subsequently and carries out compressing tablet.
Compound of the present invention or its enantiomorph or racemic mixture prevent and/or treat the medicine of infection, the for example purposes in the antibacterials in preparation.
Particularly, compound of the present invention can be with the injection form administration, although dosage can change according to treatment target, administering mode, symptom and other factor.When parenterai administration, compsn of the present invention can be processed injection formulations.Compound of the present invention is effective in quite wide dosage range.In adult's treatment, dosage range once or is several times taken at 0.1mg/kg-50mg/kg.The actual dosage of taking compound should be confirmed according to relevant situation by the doctor; These situation comprise by curer's physical state, route of administration, age, body weight, the patient individual reaction to medicine; Severity of patient's symptom or the like, therefore above-mentioned dosage range also limits scope of the present invention never in any form.
Compared with prior art, N-formyl hydroxylamine compound of the present invention is at room temperature deposited stable, has better as stability of drug.
Embodiment
Below in conjunction with embodiment the present invention is done further explanation.These embodiment are intended to help to set forth the content of invention rather than limit scope of the present invention.
Embodiment 1The preparation of 2-[(N-benzyloxy-N-formyl radical is amino) methyl] caproic acid
Present embodiment is the raw material that is used to prepare The compounds of this invention: 2-[(N-benzyloxy-N-formyl radical is an amino) methyl] caproic acid.
The preparation of acetoxime: in the 100mL round-bottomed flask, add entry 20mL, oxammonium hydrochloride 6.95g (0.1mol) stirs and makes the solid dissolving, splashes into acetone 6.38g (0.11mol); Room temperature reaction 1.5 hours, the ice-water bath cooling adds sodium hydroxide 4.0g (0.1mol) in batches, stirs 0.5 hour; Extracted with diethyl ether (30mL * 3), drying is steamed and is removed ether; Obtain white solid 6.79g, yield 93%, m.p.61-62 ℃.
The preparation of oxygen benzyl acetone oxime: 8.0g (0.348mol) sodium Metal 99.5 is added in the 150mL absolute ethyl alcohol, treat that sodium Metal 99.5 has all dissolved postcooling.25.4g (0.348mol) acetoxime is dissolved in 100mL absolute ethyl alcohol gained drips of solution is added in the sodium ethylate, stirred 1 hour.Again 44.1g (0.348mol) benzyl chloride slowly is added drop-wise in the reaction mixture.React after 5 hours, steam and remove partial solvent, add 20mL water, extracted with diethyl ether (100mL * 3), combining extraction liquid after the drying, removes solvent under reduced pressure, gets 53.9g oxygen benzyl acetoxime, productive rate 95%.
1HNMR(300MHz，CDCl
3)：δ＝1.75(s，6H)，4.857(s，2H)，7.25(s，5H)。
The preparation of oxygen benzyl hydroxylamine hydrochloride: 20.0g oxygen benzyl acetone oxime is joined in the 25mL concentrated hydrochloric acid in batches heating in water bath to 60 ℃ reaction 3 hours.Flask is distilled on rotatory evaporator, steam except that most of solvent will have a large amount of solids and separate out suction filtration; And with a little ethanol and ETHYLE ACETATE wash solids, concentrated mother liquor has solid again and separates out; Obtain 16.7g oxygen benzyl hydroxylamine hydrochloride altogether, yield 85%, m.p.232-235 ℃.
The preparation of N-benzyloxy methane amide: in the 250mL round-bottomed flask, add 10.0g (62.7mmol) oxygen benzyl hydroxylamine hydrochloride, 120mL ethanol, 5.0g (0.125mol) sodium hydroxide, 23.2g (313.5mmol) ethyl formate; Stirring at room 1 day removes most of solvent under reduced pressure, divides three extractions with the 120mL ether; 1mol/L salt acid elution, saturated common salt water washing, drying; Remove solvent under reduced pressure, obtain colourless liquid 6.6g, yield 70%.
1H?NMR(300MHz，CDCl
3)：δ＝4.65(m，2H)，7.16-7.18(m，2H)，7.21-7.24(m，2H)，7.27(s，1H)，7.98，8.21(s，1H)。
The preparation of 2-butyl malonic acid diethyl ester: in the 500mL flask with three necks,round bottom, add absolute ethyl alcohol 150mL; Sodium Metal 99.5 8.0g (0.35mol) treats that sodium reacts completely, and is chilled to room temperature; Slowly splash into 52.9g (0.33mol) ethyl malonate; Reacted 1 hour, and added 45.2g (0.33mol) bromination of n-butane again, add the back and refluxed 2 hours.Remove most of ethanol under reduced pressure, add 70mL water, isolate organic phase, ethyl acetate extraction water (50mL * 2); Merge organic phase, drying removes ETHYLE ACETATE under reduced pressure, underpressure distillation; Collect 105-110 ℃/1.3kpa cut, obtain colourless liquid 46.7g, yield 65%.
1H?NMR(300MHz，CDCl
3)：δ＝0.86-0.93(t，3H)，1.24-1.40(m，10H)，1.85-1.93(m，2H)，3.27-3.34(t，3H)，4.15-4.24(q，4H)。
The preparation of 2-butyl malonic acid: in the 500mL round-bottomed flask, add entry 30mL, ethanol 120mL, Pottasium Hydroxide 30g (0.54mol), stirring is dissolved Pottasium Hydroxide fully, adds 43.2g (0.2mol) 2-butyl malonic acid diethyl ester, reflux 3 hours.Steam and remove most of solvent, add 70mL water, place ice-water bath, transfer to PH＜2 with 5mol/L hydrochloric acid; Ethyl acetate extraction (120mL * 3) merges organic phase, washing, saturated common salt water washing; Drying, steaming desolventizes and obtains white solid 31.1g, yield 90%, m.p.105-107 ℃.
The preparation of 2-butylacrylic acid: in three mouthfuls of round-bottomed flasks of 250mL, add 2-butyl malonic acid 19.5g (0.122mol), ethanol 110mL, 37% formalin 47mL stirs and makes the solid dissolving, slowly splashes into piperidinyl-1 2.3g (0.145mol), adds in 20 minutes.Stirred 1 hour, and be heated to 72 ℃, react half a hour, reheat refluxed 2 hours.Steam and remove most of solvent, ethyl acetate extraction (80mL * 3), 5mol/L salt acid elution organic layer; The saturated common salt water washing, drying removes ETHYLE ACETATE under reduced pressure; Add the 150mL normal hexane, place refrigerator overnight, filter; Remove normal hexane under reduced pressure and obtain purer 2-butylacrylic acid 2.8g, yield 82%.
1H?NMR(300MHz，CDCl
3)：δ＝0.92(t，J＝7.2Hz，3H)，1.29-1.39(m，2H)，1.41-1.53(m，2H)，2.28-2.39(m，2H)，5.65(d，J＝1.2Hz，1H)，6.29(d，J＝1.2Hz，1H)，11.90(br，1H)。
The preparation of 2-butylacrylic acid ethyl ester: in the 100mL round-bottomed flask, add 2-butylacrylic acid 10.0g (78.1mmol), absolute ethyl alcohol 50mL, vitriol oil 1mL; Reflux 8 hours; Steam and remove most of solvent, extract saturated NaHCO with the 100mL methylene dichloride at twice
3Washing, the saturated common salt water washing, drying removes solvent under reduced pressure, obtains colourless liquid 9.75g, yield 80%.
1H?NMR(300MHz，CDCl
3)：δ＝0.84-0.92(t，J＝8.1Hz，3H)，1.25-1.27(t，J＝7.2Hz，3H)，1.31-1.57(m，6H)，4.11-4.23(m，2H)，5.58(s，1H)，6.11(s，1H)。
The preparation of 2-[(N-benzyloxy-N-formyl radical is amino) methyl] NSC 8882: in the 150mL round-bottomed flask, add 10.0g (66.2mmol) N-benzyloxy methane amide; 15.5g (99.3mmol) 2-butylacrylic acid ethyl ester; The 50mL acetonitrile, DBU 10.1g (66.2mmol), N
2Protection, reflux 7 hours removes most of solvent under reduced pressure; Add the 100mL methylene dichloride and extract 1mol/L salt acid elution, saturated common salt water washing at twice; Drying, steaming desolventizes, and silicagel column separates (sherwood oil: ETHYLE ACETATE: methylene dichloride=6: 1: 1); Obtain the 17.4g colourless liquid, yield 85%.
1H?NMR(300MHz，CDCl
3)：δ＝0.88(t，J＝6.9Hz，3H)，1.20-1.28(m，7H)，1.48-1.60(m，2H)，2.70(m，1H)，3.24-4.20(m，4H)，4.70-4.97(m，2H)，7.38(s，5H)，7.94，8.15(s，1H)。
The preparation of 2-[(N-benzyloxy-N-formyl radical is amino) methyl] caproic acid: in the 150mL round-bottomed flask, add 5.0g (16.3mmol) 2-[(N-hydroxy-n-formyl radical is amino) methyl] NSC 8882,50mL methyl alcohol, 25mL water, 0.75g (17.9mmol) LiOHH
2O, stirred overnight adds suitable quantity of water, dichloromethane extraction (20mL * 2).Water layer with the 1mol/L hcl acidifying to PH＜3, dichloromethane extraction (70mL * 3), saturated common salt water washing; Drying concentrates and obtains product, and silicagel column separates (sherwood oil: ETHYLE ACETATE: methylene dichloride=6: 1: 1; Add a spot of formic acid), obtain little yellow liquid 3.39g, yield 75%.
1H?NMR(300MHz，CDCl
3)：δ＝0.87(t，J＝7.2Hz，3H)，1.30(m，4H)，1.49-1.61(m，2H)，2.74(m，1H)，3.24-3.85(m，2H)，4.75-4.97(m，2H)，7.27-7.41(m，5H)，7.99-8.16(m，1H)，10.91(br，1H)。
Embodiment 2The preparation of 2-aminomethyl benzimidazole
Present embodiment is the raw material that is used to prepare The compounds of this invention: the 2-aminomethyl benzimidazole, it is a kind of in the compound shown in the formula III.
The reaction formula of present embodiment is following:
In the 100mL round-bottomed flask, add 1.05g (9.72mmol) O-Phenylene Diamine, 1.71g (9.72mmol) N-t-butoxycarbonyl glycine, 30mL THF; Stirring is dissolved substrate fully, is cooled to 0 ℃, adds 2.41g (11.7mmol) DCC in batches; Add the back ice bath and react half a hour, room temperature reaction spends the night.Filter, boil off solvent, silicagel column roughing out (methylene dichloride: methyl alcohol=25: 1) obtain product 2.24g, productive rate 86.9%.
The gained solid is dissolved in the 15mL Glacial acetic acid min. 99.5, is heated to 72 ℃, reacted 8 hours, remove most of acetic acid under reduced pressure, add the 100mL methylene dichloride and extract saturated NaHCO at twice
3Washing, the saturated common salt water washing, drying concentrates and obtains product, and silicagel column separates (methylene dichloride: methyl alcohol=30: 1), obtain white solid 1.72g, yield 82.4%, m.p.181-183 ℃.
1H?NMR(300MHz，CDCl
3)：δ＝1.45(s，9H)，2.13(s，1H)，4.54(d，J＝6.3Hz，2H)，6.12(br，1H)，7.25(d，J＝16.2Hz，2H)，7.57(d，J＝16.2Hz，2H)；IR(KBr，v/cm
-1)3343，1686，1529，1286，1173，736。
Above-mentioned white solid is dissolved in the methanol solution of 20mL 2mol/L HCl, stirred overnight, steaming desolventizes, and filters, and the ether washing obtains the hydrochloride 1.25g of white solid 2-aminomethyl benzimidazole, yield 95%; Remove hydrogenchloride with the organic bases triethylamine and promptly get the 2-aminomethyl benzimidazole.
Embodiment 3N-(benzimidazolyl-2 radicals-yl) the preparation of methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide
Present embodiment is a kind of preparation method in the compound shown in the formula I.
In the 50mL round-bottomed flask, add 1.0g (5.72mmol) CDMT and 1.45g (5.20mmol) 2-[(N-benzyloxy-N-formyl radical is amino) methyl] caproic acid and be dissolved in dry methylene chloride (30mL); Cryosel is bathed and is dripped 683mg (6.76mmol) N-methylmorpholine down; React after 4 hours; Add 764mg (5.20mmol) 2-aminomethyl benzimidazole (among the III a kind of), cryosel bathes that reaction is after 2 hours down, and room temperature reaction spends the night.Remove by filter deposition,, merge washing lotion and filtrating, use 0.5mol/L hydrochloric acid, saturated NaHCO successively with a small amount of washed with dichloromethane deposition
3, the saturated common salt water washing, concentrating under reduced pressure behind the anhydrous sodium sulfate drying, with this crude product with silicagel column separate (methylene dichloride: methyl alcohol=20: 1) white solid 1.96g (II's is a kind of), yield 89%, m.p.114-117 ℃.
1H?NMR(300MHz，CDCl
3)：δ＝0.82(t，J＝6.3Hz，3H)，1.25-1.44(m，5H)，1.64(br，1H)，2.64(br，1H)，3.66-3.90(m，2H)，4.36-4.42(dd，J＝4.5Hz，15.0Hz，1H)，4.71(br，3H)，7.21-7.30(m，6H)，7.51(br，3H)，7.96(s，1H)；IR(KBr，v/cm
-1)：3320，2929，1658，1541，1442，1125.
0.8g (1.96mmol) N-(methyl-2-of benzimidazolyl-2 radicals-yl) [(N-benzyloxy-N-formyl radical is amino) methyl] hexanamide (among the II a kind of) is dissolved in the 20mL absolute ethyl alcohol; The Pd/C (moisture 65%) that adds 200mg massfraction 10%; Hydrogenation under the normal temperature and pressure; TLC detects after 3 hours, reacts completely.Filter, concentrate white solid, silicagel column separates (methylene dichloride: methyl alcohol=20: 1), obtain white solid 0.57g (among the I a kind of), yield 92%, m.p.85-86 ℃.IR(KBr)cm
-1：3279(-NH-)，2956，2930(CH，aliphatic)，1655(＞C＝O)，1540(-C＝C-)，1384(-CHO)，743(-Ar-)；
1H?NMR(300MHz，DMSO，δppm)：0.82-0.83(t，3H，J＝3.6Hz，CH
3)，1.23-1.44(m，6H，CH
2)，2.64-2.73(m，1H，CH)，3.39-3.80(m，2H，CH
2)，4.29-4.76(m，2H，CH
2)，7.14-7.19(m，2H，Ar-H)，7.51(m，2H，Ar-H)，7.87(brs，0.49H，CHO)，8.30(brs，0.51H，CHO)；HRMS(ESI)：[M+H]
+calcd?m/z319.1771，found?319.1761.
Embodiment 4-13
According to the preparation method who is similar to embodiment 3, select different substituted III to replace the 2-aminomethyl benzimidazole, can make different I respectively.
It is following that the nuclear-magnetism of the compound of embodiment 4-13 preparation is measured the result:
N-(5-tolimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.82-0.84 (t, 3H, J=4.2Hz, CH
3), 1.23-1.48 (m, 6H, CH
2), 2.39 (s, 3H, CH
3), 2.61-2.72 (m, 1H, CH), 3.38-3.80 (m, 2H, CH
2), 4.24-4.76 (m, 2H, CH
2), 6.96-7.01 (m, 1H, Ar-H), 7.29 (m, 1H, Ar-H), 7.37-7.39 (m, 1H, Ar-H), 7.87 (brs, 0.49H, CHO), 8.30 (brs, 0.51H, CHO).
N-(5-methoxyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.84 (t, 3H, CH
3), 1.23-1.47 (m, 6H, CH
2), 2.58-2.72 (m, 1H, CH), 3.35-3.77 (m, 4H, CH
2), 4.24-4.73 (m, 2H, CH
2), 6.77-6.81 (m, 1H, Ar-H), 6.99 (m, 1H, Ar-H), 7.37-7.40 (d, 1H, J=8.7Hz, Ar-H), 7.87 (brs, 0.5H, CHO), 8.30 (brs, 0.50H, CHO).
N-(5-oxyethyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.84 (t, 3H, CH
3), 1.23 (m, 5H, CH
2), 1.31-1.36 (t, 3H, J=13.8Hz, CH
3), 1.44 (m, 1H, CH
2), 2.62-2.72 (m, 1H, CH), 3.35-3.79 (m, 2H, CH
2), 4.00-4.02 (m, 2H, CH
2), 4.24-4.73 (m, 2H, CH
2), 6.78 (m, 1H, Ar-H), 6.98 (m, 1H, Ar-H), 7.36-7.39 (d, 1H, J=8.1Hz, Ar-H), 7.87 (brs, 0.49H, CHO), 8.30 (brs, 0.51H, CHO).
N-(methyl-2-of 5-itrile group benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.79-0.83 (t, 3H, J=13.2Hz, CH
3), 1.21-1.38 (m, 6H, CH
2), 2.66-2.74 (m, 1H, CH), 3.38-3.77 (m, 2H, CH
2), 4.41-4.67 (m, 2H, CH
2), 7.55-7.57 (m, 1H, Ar-H), 7.66-7.69 (m, 1H, Ar-H), 8.05 (m, 1H, Ar-H), 7.86 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
N-(5-methoxycarbonyl benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.80-0.82 (t, 3H, J=6.3Hz, CH
3), 1.22-1.44 (m, 6H, CH
2), 2.67-2.74 (m, 1H, CH), 3.41-3.80 (m, 2H, CH
2), 3.86 (s, 3H, CH
3), 4.38-4.71 (m, 2H, CH
2), 7.59-7.62 (m, 1H, Ar-H), 7.82-7.84 (m, 1H, Ar-H), 8.12 (m, 1H, Ar-H), 7.87 (brs, 0.55H, CHO), 8.31 (brs, 0.46H, CHO).
N-(5-chloro benzimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1HNMR (300MHz, DMSO, δ ppm): 0.79-0.82 (t, 3H, J=6.9Hz, CH
3), 1.22-1.43 (m, 6H, CH
2), 2.64-2.73 (m, 1H, CH), 3.35-3.78 (m, 2H, CH
2), 4.33-4.68 (m, 2H, CH
2), 7.19 (m, 1H, Ar-H), 7.50-7.56 (m, 2H, Ar-H), 7.86 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
N-(5,6-benzoxazole dimethyl-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.82-0.84 (t, 3H, J=6.9Hz, CH
3), 1.24-1.43 (m, 6H, CH
2), 2.21-2.35 (s, 6H, CH
3), 2.67-2.74 (m, 1H, CH), 3.38-3.79 (m, 2H, CH
2), 4.28-4.70 (m, 2H, CH
2), 6.90-7.14 (m, 2H, Ar-H), 7.87 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
N-(6-methylbenzothiazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.80-0.83 (t, 3H, J=6.9Hz, CH
3), 1.23-1.46 (m, 6H, CH
2), 2.35 (s, 3H, CH
3), 2.66-2.75 (m, 1H, CH), 3.35-3.76 (m, 2H, CH
2), 4.25-4.76 (m, 2H, CH
2), 7.13 (m, 1H, Ar-H), 7.34 (m, 1H, Ar-H), 7.58 (m, 1H, Ar-H), 7.87 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
N-(6-first aminocarbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.79-0.83 (t, 3H, J=6.9Hz, CH
3), 1.23-1.44 (m, 6H, CH
2), 2.63 (s, 3H, CH
3), 2.63-2.72 (m, 1H, CH), 3.34-3.74 (m, 2H, CH
2), 4.26-4.76 (m, 2H, CH
2), 7.16 (m, 1H, Ar-H), 7.35 (m, 2H, Ar-H), 7.87 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
N-(6-first carbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide:
1H NMR (300MHz, DMSO, δ ppm): 0.81-0.84 (t, 3H, J=6.9Hz, CH
3), 1.24-1.46 (m, 6H, CH
2), 2.45 (s, 3H, CH
3), 2.65-2.74 (m, 1H, CH), 3.36-3.74 (m, 2H, CH
2), 4.25-4.74 (m, 2H, CH
2), 7.09 (m, 1H, Ar-H), 7.38 (m, 2H, Ar-H), 7.87 (brs, 0.51H, CHO), 8.30 (brs, 0.49H, CHO).
Embodiment 14The biological activity determination of The compounds of this invention
Experiment material: substratum: microorganism identification medium pH 7.9 ± 0.1 Beijing three medicine scientific and technological development company lot numbers: 020425.Bacterial classification: standard gold staphylococcus aureus CMCC 26112, standard klebsiella pneumoniae CMCC 46117, above bacterial classification is all purchased in Nat'l Pharmaceutical & Biological Products Control Institute.
The preparation of sample: accurate weighing sample 1.6mg with after the 1-2mL DMSO dissolving, is diluted to 5mL with SPSS earlier; Get 2mL with 0.22 μ m diameter membrane filtration degerming, be diluted to 5mL with aseptic broth culture again, obtain concentration and be: the soup of 128 μ g/mL, use broth culture to carry out doubling dilution then and obtain concentration and be: 64,32,16,8, the soup of 4,2 μ g/mL is subsequent use.
The preparation of bacterium liquid: the standard gold staphylococcus aureus of preserving, the lyophilized powder of standard bacillus canalis capsulatus are got a little with transfering loop, draw gently in M-H nutrient agar (autoclaving solidifies the back) plate, behind the cultivation 48h, grow moistening, fresh bacterium colony.Get in a little sterile saline of going into 3-5mL with transfering loop, carry out than after turbid with 0.5,1 Maxwell turbidity pipe, get the bacterium liquid of 150 μ l and go in the broth culture of 15mL, bacterium reaches 10 in the bacterium liquid
5, subsequent use.
The mensuration of sample: the bacterium liquid of broth culture and 200 μ l that on 96 orifice plates, adds 200 μ l respectively is as contrast, and the different concns sample that adds compound sample of the present invention and 1 control sample (each sample repeats 2 times) in other holes respectively is 100 μ l, and bacterium liquid 100 μ l; The medicine final concentration is respectively 32; 16,8,4; 2,1 μ g/mL.With observed clarification minimum concentration is MIC, result such as table 1.
The external bacteriostatic activity of table 1 compound (MIC, μ g/mL)
Can know that by last table 1 compound that obtains among the embodiment 3,7,9 and 11 has stronger restraining effect (MIC＜1 μ g/mL) external to standard gold staphylococcus aureus (gram-positive microorganism).
Embodiment 15:The preparation of tablet
Every tablet prepn that contains the 10mg activeconstituents is following:
Prescription consumption/sheet
The compound 10mg of embodiment 3
Microcrystalline Cellulose 35mg
Starch 45mg
Vinylpyrrolidone polymer 4mg
CMS sodium salt 4.5mg
Magnesium Stearate 0.5mg
Talcum powder 1mg
Amount to 100mg
The preparation method: get 50 amounts, activeconstituents (being the compound of embodiment 1), starch and Mierocrystalline cellulose are sieved, and thorough mixing; Polyvinylpyrrolidonesolution solution is mixed with above-mentioned powder; Sieve, make wet granular in 50-60 ℃ of drying, with the CMS sodium salt; Magnesium Stearate and talcum powder sieve in advance, join compressing tablet in the above-mentioned particle then.
Embodiment 16:The preparation of injection liquid
Prescription:
The compound 100mg of embodiment 7
Sorbityl monododecanoate 100mg
Hydrocerol A 100mg
Zero(ppm) water 200ml
The preparation method: with the NaOH adjust pH is 7.0-7.5, adds 0.1% activated carbon, stirs 30 minutes under the room temperature, filters, and by 50 milliliters of packing of every peace bottle, 120 ℃ of high-temperature sterilizations promptly got injection liquid in 30 minutes, and specification is 25mg.
Embodiment 17:Capsular preparation
It is following that every capsule contains the capsular preparation of 100mg activeconstituents:
Prescription consumption/capsule
The compound 100mg of embodiment 10
Starch 45mg
T 46155 dehydration sorb 1mg
CMS sodium salt 2mg
Magnesium Stearate 2mg
Amount to 150.0mg
The preparation method: get 50 amounts, activeconstituents and starch are sieved, and thorough mixing; Polyvinylpyrrolidonesolution solution is mixed with above-mentioned powder, sieve, make wet granular in 50-60 ℃ of drying; With the CMS sodium salt, Magnesium Stearate sieves in advance, is encased in the capsule then.
Abovely described the present invention in detail, to those skilled in the art, should be understood that above-mentioned embodiment should not be understood that to limit scope of the present invention with reference to embodiment.Therefore, can make various changes and improvement to embodiment of the present invention without departing from the spirit and scope of the present invention.
Embodiment 18:The mensuration of The compounds of this invention stability
The study on the stability method: sample is placed in the weighing bottle in right amount, the about 1mm of thickness of sample, uncovered placing under 40 ℃, the condition of RH75%, the impurity of observing sample after 10 days changes.
The HPLC condition determination: with octadecylsilane chemically bonded silica (5 μ granularity) is weighting agent; Moving phase is water: methyl alcohol=88: 12 (regulating with 0.3% Glacial acetic acid min. 99.5+3.0ml triethylamine about the pH value to 7.1 of moving phase); The detection wavelength is 215nm, and the separating size of sample main peak and adjacent impurity peaks should meet the requirements.Make the sample peak between 5-10 minute according to different samples adjustment methanol content.
Measuring method: the compound of the present invention and existing (the R)-2-butyl-N that get embodiment 3, embodiment 9 preparations
4-hydroxy-n
1-[1-(S)-(benzimidazolyl-2 radicals-yl)-2-methyl] propyl succinimide acid amides (being control sample 1) and (R)-2-butyl-N
4-hydroxy-n
1-(5-chloro-benzoxazole-2-yl) methyl succinic diamide (being control sample 2) (embodiment 1 and embodiment 11 referring to one Chinese patent application 200810053273.7 prepare); Add the moving phase dissolving and process the need testing solution that contains 100 μ g among every 1ml approximately; Measure contrast solution 20 μ l and inject liquid chromatograph; 2 times of record color atlas to principal constituent peak RT are investigated foreign matter content in the sample with normalization method.Measure the result and see table 2.
The stability of table 2 test sample is measured the result
Can be found out that by last table 2 impurity level was more or less the same before and after compound of the present invention was placed, and the product of prior art was placed after 10 days, impurity level obviously increases, and this explains that compound of the present invention compares with the sample of prior art and have stability preferably.
Claims (9)
1. compound or its enantiomorph or the racemic mixture shown in the formula I,
Wherein, X is O, NH or S; R
1Be H, C
1-C
5The straight or branched alkyl; R
2And R
3Be H, C independently
1-C
5Straight chained alkyl ,-OR ' ,-SR ' ,-halogen ,-CN ,-CONR ' ,-COOR ' or-COR ', wherein, R ' is H, C
1-C
5The straight or branched alkyl.
2. compound according to claim 1 or its enantiomorph or racemic mixture is characterized in that, X is O, NH or S; R
1Be H, sec.-propyl, methyl, ethyl, n-propyl, normal-butyl, isobutyl-or the tertiary butyl; R
2And R
3Be independently H, methyl, ethyl, n-propyl, sec.-propyl, hydroxyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy, first sulfydryl, second sulfydryl, fluorine, chlorine, bromine ,-CN ,-COOR ', CONR ' or-COR '; Wherein, R ' is methyl, ethyl, n-propyl or sec.-propyl.
3. compound according to claim 1 and 2 or its enantiomorph or racemic mixture is characterized in that, said compound is:
N-(methyl-the 2-of benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-tolimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-oxyethyl group benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(methyl-the 2-of 5-itrile group benzimidazolyl-2 radicals-yl) [(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-methoxycarbonyl benzo imidazoles-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5-chloro benzimidazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(5,6-benzoxazole dimethyl-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-methylbenzothiazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide;
N-(6-first aminocarbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide; Or
N-(6-first carbonyl benzoxazole-2-yl) methyl-2-[(N-hydroxy-n-formyl radical is amino) methyl] hexanamide.
4. the preparation method of each described compound or its enantiomorph or racemic mixture in the claim 1 to 3 is characterized in that the preparation method of said compound comprises the steps:
(1) compound shown in the formula III and 2-[(N-benzyloxy-N-formyl radical amino) methyl] caproic acid is at catalyzer, and for example 4,6-dimethoxy-2-chloro-1; 3; Under the effect of 5-triazine (CDMT) and/or N-methylmorpholine (NMM), with organic solvent, for example methylene dichloride is a solvent; Under room temperature, react the compound shown in the production II at 0 ℃; And
(2) compound shown in the formula II that step (1) is generated is with reductive agent, for example with H
2Reduce with 10%Pd/C, with organic solvent, for example ethanol is solvent, reacts deprotection under the room temperature, obtains the compound shown in the formula I;
Wherein, R
1, R
2And R
3Have like each defined implication in the claim 1 to 3.
5. pharmaceutical composition, this pharmaceutical composition comprises each described compound or its enantiomorph or racemic mixture in the claim 1 to 3.
6. pharmaceutical composition according to claim 5 is characterized in that, said pharmaceutical composition also comprises one or more pharmaceutically acceptable carriers, vehicle and/or thinner.
7. according to claim 5 or 6 described pharmaceutical compositions, it is characterized in that said pharmaceutical composition is solid orally ingestible, liquid oral medicine or injection.
8. according to each described pharmaceutical composition in the claim 5 to 7; It is characterized in that said pharmaceutical composition is tablet, dispersible tablet, enteric coated tablet, chewable tablet, oral cavity disintegration tablet, capsule, sugar-coat agent, granule, dry powder doses, oral solution, the little pin of injection, injection freeze-dried powder or infusion solutions.
9. each described compound or its enantiomorph or racemic mixture prevent and/or treat the medicine of infection, the for example purposes in the antibacterials in preparation in the claim 1 to 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010512017.7A CN102452986B (en) | 2010-10-20 | 2010-10-20 | N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010512017.7A CN102452986B (en) | 2010-10-20 | 2010-10-20 | N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102452986A true CN102452986A (en) | 2012-05-16 |
| CN102452986B CN102452986B (en) | 2014-07-02 |
Family
ID=46036715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010512017.7A Expired - Fee Related CN102452986B (en) | 2010-10-20 | 2010-10-20 | N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102452986B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362162A (en) * | 2016-05-11 | 2017-11-21 | 如东瑞恩医药科技有限公司 | The antitumor application thereof of spiral shell three-membered ring, spiral shell five-membered ring class peptide deformylase inhibitor containing 2 |
| CN107365303A (en) * | 2016-05-11 | 2017-11-21 | 如东瑞恩医药科技有限公司 | The antibacterial applications of spiral shell three-membered ring, spiral shell five-membered ring class peptide deformylase inhibitor containing 2 |
| CN109369449A (en) * | 2018-12-25 | 2019-02-22 | 浙江工业大学 | A kind of method of synthesizing oxime ether |
| CN109956884A (en) * | 2019-04-28 | 2019-07-02 | 曹文兵 | A kind of preparation method of Phenylmethoxyamine hydrochloride |
| CN114181107A (en) * | 2021-11-08 | 2022-03-15 | 宁波睿田科技有限公司 | Synthesis method of benzyloxy amine hydrochloride |
-
2010
- 2010-10-20 CN CN201010512017.7A patent/CN102452986B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| LING LIN ET AL.: "Synthesis and antimicrobial activities of novel peptide deformylase inhibitors", 《ARKIVOC》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362162A (en) * | 2016-05-11 | 2017-11-21 | 如东瑞恩医药科技有限公司 | The antitumor application thereof of spiral shell three-membered ring, spiral shell five-membered ring class peptide deformylase inhibitor containing 2 |
| CN107365303A (en) * | 2016-05-11 | 2017-11-21 | 如东瑞恩医药科技有限公司 | The antibacterial applications of spiral shell three-membered ring, spiral shell five-membered ring class peptide deformylase inhibitor containing 2 |
| CN107365303B (en) * | 2016-05-11 | 2019-12-13 | 如东瑞恩医药科技有限公司 | Antibacterial application of spirotricyclic and spiropentacyclic peptide deformylase inhibitor |
| CN107362162B (en) * | 2016-05-11 | 2019-12-13 | 如东瑞恩医药科技有限公司 | Antitumor application of spirotricyclic and spiropentacyclic peptide deformylase inhibitor |
| CN109369449A (en) * | 2018-12-25 | 2019-02-22 | 浙江工业大学 | A kind of method of synthesizing oxime ether |
| CN109956884A (en) * | 2019-04-28 | 2019-07-02 | 曹文兵 | A kind of preparation method of Phenylmethoxyamine hydrochloride |
| CN109956884B (en) * | 2019-04-28 | 2022-03-08 | 浙江圣安化工股份有限公司 | Preparation method of benzyloxyamine hydrochloride |
| CN114181107A (en) * | 2021-11-08 | 2022-03-15 | 宁波睿田科技有限公司 | Synthesis method of benzyloxy amine hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102452986B (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101031572B (en) | (R/S) rifamycin derivatives, their preparation and pharmaceutical compositions | |
| DE60117861T2 (en) | ANTIMICROBIAL CHINOLON DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| CN102452986B (en) | N-formyl hydroxylamine compounds, preparation method thereof, and purposes thereof | |
| CN101553470A (en) | Antibacterial quinoline derivatives | |
| CN101918417A (en) | Pyridine derivative substituted with heterocycle and phosphonoxymethyl group and antifungal agent containing the same | |
| DE102007042154A1 (en) | Arylsulfonylaminomethyphosphonsäure derivatives, their preparation and their use as medicaments | |
| CN102452998B (en) | N-formyl hydroxylamine compound and its preparation method and use | |
| CN105682655A (en) | Antimicrobial compounds | |
| US8530512B2 (en) | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | |
| CN102452958A (en) | N-formyl hydroxylamine compounds, preparation method, and use thereof | |
| AU2009269842B2 (en) | Use of indole derivatives as NURR-1 activators for treating Parkinson's disease | |
| CN111635309A (en) | Novel antipyretic analgesic drug and preparation method and application thereof | |
| CN101209974A (en) | Hydroxamic acids derivatives and use thereof | |
| EP0397044B1 (en) | Arylsulfonamides, medicines containing these compounds and process for their preparation | |
| CN105399737B (en) | Oxazolidinone compounds and application thereof | |
| CN107739371B (en) | Tetrahydrocarbazole micromolecule organic compound, application thereof in preparing antibacterial drugs and preparation method thereof | |
| CN107400126A (en) | Novel oxazolidinone class compound and preparation method thereof and application medically | |
| CN102503906A (en) | Formyl hydroxylamine type peptide deformylase inhibitor containing oxazole ring, as well as preparation method and use thereof | |
| EP2524922B1 (en) | Preparation method of optically active s-(-)-prulifloxacin | |
| CN102964357A (en) | Faropenem sodium and tablet thereof | |
| CN101386620B (en) | Thiazole derivative and preparation method and application thereof | |
| CN101397297A (en) | Aminothiazole derivates, preparation method and use thereof | |
| CN110981888A (en) | N-aryl dithiopyrryl ketonuria and amino ester derivatives, preparation and application thereof | |
| CN103304556B (en) | Schiff bases compounds containing chromene, Preparation Method And The Use | |
| CN107648217A (en) | Neo-garcinolic acid or derivatives thereof is being prepared for preventing and/or treating by the purposes in the medicine of bacterial relevant disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140702 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |